Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by endocrine tumors of the parathyroid, anterior pituitary and pancreatic islets. The MEN1 gene [1] encodes a protein of 610 amino acids ± menin ± located predominantly in the nucleus [2, 3] . In MEN1 carriers, inactiva− ting mutations give rise to a truncated product consistent with menin acting as a tumor suppressor [4] . The biological properties and roles that menin plays physiologically and the mechanisms by which menin loss leads to tumorigenesis in select tissues are unclear, but are currently under intensive investigation.
Abstract
Pituitary: Menin is a Smad3−interacting protein; inactivation of menin blocks transforming growth factor (TGF)−b and activin signaling, antagonizing their growth−inhibitory properties in anterior pituitary cells. Menin is also required for the activin−in− duced inhibition of prolactin expression mediated by the Smads and the transcription factor, Pit−1. The interaction between me− nin and Smad3 is direct. Parathyroid: In cultured parathyroid cells from uremic hemodialysis patients, in which the menin sig− naling pathways are probably still intact, menin inactivation achieved by menin antisense oligonucleotides leads to loss of TGF−b inhibition of parathyroid cell proliferation and parathyroid hormone (PTH) secretion. Moreover, TGF−b does not affect the proliferation and PTH production of parathyroid cells from mul− tiple endocrine neoplasia type 1 (MEN1) patients. Osteoblast:
Men1−null mouse fetuses that die at day 12 or earlier have cra− nial/facial hypoplasias implicating menin in bone development. Menin is required for the commitment of multipotential mes− enchymal stem cells into the osteoblast lineage. This is achieved by menin interacting physically and functionally with bone mor− phogenetic protein (BMP)−2 regulated Smads, such as Smad1 and Smad5, and the key osteoblast regulator, Runx2. These interac− tions are lost as the committed osteoblasts differentiate further at which time menin interacts with Smad3, mediating the nega− tive regulation of Runx2 by TGF−b. Menin also suppresses osteo− blast maturation, partly by inhibiting the differentiation actions of JunD.
for early development [8, 9] . It may be involved in telomere biol− ogy [10, 11] and DNA replication and repair [12, 13] .
Menin interacts with several transcription regulators including Smads, JunD and NF−kB, and modulates their activities [14] . The focus of this review will be on menin's interaction with Smads and the relevance for TGF−b superfamily member signaling with respect to control of pituitary and parathyroid cell proliferation (and its dysregulation providing a stimulus to neuroendocrine tumorigenesis if menin activity is lost [15] ). In addition, this re− view will deal with the role that menin plays in osteoblastogen− esis and osteoblast differentiation.
The TGF−b Signaling Pathway TGF−b signals through type I and type II serine/threonine kinase cell membrane receptors (Fig. 1) . The type II receptor is constitu− tively phosphorylated and, when activated by binding of the TGF−b ligand, recruits and transphosphorylates the type I recep− tor. The activated type I receptor phosphorylates the receptor− regulated Smads (Smad2 and Smad3) and their association with the common partner, Smad4. The Smad3/Smad4 complex then translocates to the nucleus to activate specific genes [16, 17] .
The cytokine TGF−b causes growth inhibition of most cell types; loss of TGF−b signaling may push the cell towards inappropriate growth that ultimately results in tumor formation. One way that some oncoproteins abrogate normal cellular growth control is by blocking TGF−b signaling. Inactivating mutations in various com− ponents of the TGF−b /Smad signaling pathway are found in nu− merous types of human cancer. The TGF−b type II receptor is of− ten inactivated by mutation in colon and gastric cancers with mi− crosatellite instability [18] . Deletion or point mutation in the TGF−b type I receptor gene is found in pancreatic, biliary, colorec− toral, cervical, and breast cancers [19 ± 22] . The tumor suppressor gene, Smad4, is mutated in nearly half of all pancreatic cancers [23] and to a lesser extent in other types, such as esophageal ade− nocarcinoma [24] , head and neck carcinoma [25] , hepatocellular carcinoma [26] , neuroblastoma [27] , breast cancer [28] and lung cancer [29] . While no mutations in the Smad3 gene have been re− ported to date, the Smad2 gene is mutated in colon, head and neck, as well as lung carcinomas [30 ± 32] . We hypothesized that menin, acting as a tumor suppressor, may be involved in the growth inhibitory actions of TGF−b in endocrine cells.
Menin and Anterior Pituitary Cells
In the rat anterior somatolactotrope GH4C1 cell line, TGF−b stim− ulates menin expression rapidly and dose−dependently [33] . To explore the involvement of menin in the TGF−b−signaling path− way, GH4C1 cells were stably transfected with antisense menin cDNA (AS); markedly reduced menin expression was demon− strated. TGF−b's ability to stimulate menin accumulation was blocked in the AS cells. In addition, antisense menin antagonized the normal inhibitory effect of TGF−b on cell proliferation as measured by cell number, tritiated thymidine uptake and cell viability assays [33] .
Menin Inactivation Inhibits TGF−b−induced Transcriptional Activity
We examined the effects of menin antisense on TGF−b−mediated transcriptional responses. For this, we used the human hepato− ma HepG2 cell line that has been well−characterized with respect to TGF−b effects. TGF−b greatly increased luciferase activity in the absence of antisense menin in these cells when transfected with the TGF−b−responsive plasminogen activator inhibitor−1 (PAI−1) promoter luciferase reporter gene construct (3TP−Lux). However, reduced menin expression achieved by antisense menin co− transfection markedly blocked TGF−b−induced transcriptional activity. The specificity of the response was demonstrated by the restoration of transcriptional activity with co−transfection of increasing amounts of a sense menin construct [33] .
Menin Interacts with Smad3
To examine whether menin would interact with any of the Smad proteins, COS (African green monkey kidney) cells were transi− ently transfected with cDNA coding for epitope−tagged Smad2, Smad3 or Smad4 in the presence or absence of menin cDNA. Me− nin specifically co−immunoprecipitated with Smad3, but not with Smad2 or Smad4 [33] . Both Smad2 and Smad3 co−immuno− precipitated with Smad4 in response to TGF−b, confirming the functionality of our system.
To examine whether the interaction is direct, we performed GST− Smad3 pull−down reactions with in vitro transcribed/translated full−length and deletion mutants of menin [34] . These studies showed that the interaction between menin and Smad3 is direct, and that the sequence between amino acids 101 ± 195 is critical for this. GST−menin pull−down reactions with full−length and de− letion mutants of Smad3 demonstrated that the Smad3 MH2 do− 
Reduced Menin Expression Impairs Smad3−mediated Transcriptional Activity
To explore the functional relationship of Smad3 and menin, we examined whether antisense menin would affect Smad3−medi− ated transcriptional activity. Smad3 overexpression in either HepG2 or GH4C1 cells increased transcriptional activity of the transfected 3TP−Lux construct (described above) itself and aug− mented TGF−b−induced transcriptional activity, and antisense menin significantly inhibited the Smad3−mediated transcription− al activity. The transcriptional activity was restored by co−trans− fection of the sense menin construct. These data suggest that menin functionally interacts with Smad3, and that menin inacti− vation blocks Smad3−mediated transcriptional effects in the TGF− b pathway [33] . In addition we have demonstrated that reduced menin expression achieved by the antisense technique does not affect TGF−b−induced Smad3 and Smad4 oligomerization and nu− clear translocation [33] .
Reduced Menin Expression Disrupts Smad3 Binding to DNA
The Smad3/Smad4 complex recognizes specific binding sites on gene promoters. We examined whether antisense menin would affect the DNA binding ability of the Smad3/Smad4 complex by using an electromobility shift assay (EMSA) with nuclear extracts from GH4C1 cells and a probe derived from the same promoter, that for PAI−1, used for the TGF−b responsive promoter reporter gene experiments. Levels of Smad3/Smad4−DNA complex were decreased when menin levels were reduced by antisense menin transfection with Smad3 and Smad4. Co−expression of sense me− nin restored the levels of the Smad−DNA complex. Therefore, me− nin interacts with the TGF−b pathway in the nucleus through Smad3 and inactivation of menin disrupts Smad3 binding to its cognate DNA element, thereby blocking TGF−b signaling [33] .
Thus, menin plays an important role in supporting TGF−b and Smad3 transcriptional control of cell growth, and reduced menin expression disrupts TGF−b−mediated transcription and growth inhibition. Some oncoproteins, SkiI and SnoN, inhibit the TGF−b signaling pathway through a Smad transcriptional co−repressor [35, 36] . Menin may act by blocking the effect of co−repressors, facilitating TGF−b signaling.
Pituitary adenomas are common, but in contrast to sporadic parathyroid tumors and enteropancreatic tumors, mutation of the MEN1 gene is not a major contributor to sporadic pituitary tumorigenesis. However, variable and decreased expression of the menin protein was noted by immunohistochemistry in a ser− ies of sporadic pituitary adenomas [37] . Therefore, it is likely re− duced menin expression is contributing to the more common sporadic pituitary tumorigenesis.
Activin, another member of the TGF−B superfamily, plays an im− portant role in regulating anterior pituitary gland function acting on gonadotropes, somatotropes and lactotropes. Activin is a neg− ative regulator of cell growth and prolactin (PRL) production in pituitary lactotrope cells [38] . We have demonstrated that inac− tivation of menin achieved through three different antisense technologies (cDNA antisense, oligonucleotide antisense, and siRNA) blocks activin signaling via the Smads in somatolacto− trope cells [39] . This results in an increase in PRL gene expres− sion, Pit1 gene expression, and the loss of pituitary cell growth inhibition by activin.
Menin and Parathyroid
Several local growth factors such as endothelin−1, TGF−a, fibro− blast growth factors, and insulin−like growth factors are express− ed in parathyroid cells and in some cases have been shown to stimulate the proliferation of parathyroid cells [40] . The expres− sion of TGF−b and its role in parathyroid cell function has not pre− viously been studied. We have demonstrated that TGF−b is expressed in the parathyroid, predominantly by the endocrine cells, and that TGF−b negatively regulates the proliferation and PTH production of these cells [40] .
A role for alterations in the MEN1 gene has been clearly estab− lished in the pathogenesis of sporadic primary parathyroid tu− morigenesis. It has also been shown that a substantial number of "hyperplastic" tumors from patients with uremic refractory hyperparathyroidism are monoclonal in nature. However, allelic loss of chromosome 11 markers and/or MEN1 gene inactivation has been demonstrated in only a very few of uremic types of tu− mor (see ref. [40] and its references). Thus, MEN1 gene abnor− mality rarely plays a role in the clonal emergence in uremic para− thyroid hyperplasia. Given this background, our study used tis− sue from uremic hyperparathyroidism patients as an appropriate surrogate for normal human parathyroid tissue in which the MEN1 gene is not impaired [40] .
Addition of TGF−b to parathyroid cells from patients with sec− ondary hyperparathyroidism inhibited their proliferation and PTH secretion. These responses to TGF−b were lost when menin was specifically inactivated by antisense oligonucleotides [40] . Moreover, TGF−b did not affect the proliferation and PTH produc− tion of parathyroid cells from MEN1 patients. Therefore, TGF−b is an important autocrine/paracrine negative regulator of parathy− roid cell proliferation, and PTH secretion and loss of TGF−b sig− naling due to menin inactivation may contribute to parathyroid tumorigenesis.
Chromosome 15q, where the Smad3 gene is located, has been im− plicated as the site of an as yet unidentified tumor suppressor in endocrine tumors. A significant proportion of both parathyroid and enteropancreatic tumors show loss of heterozygosity of DNA markers surrounding the Smad3 locus [41] . However, no ac− quired clonal mutations have been identified in the Smad3 pro− tein−coding exons in such tumors [41] . Other mechanisms that could lead to altered Smad3 expression in the tumors have yet to be examined. Also, intriguingly, Smad3 can serve as a tran− scriptional co−activator [42, 43] that mediates inhibition of parathyroid cell proliferation by 1,25− dihydroxyvitamin D [44] . Therefore, one way or the other, either direct gene mutation or epigenetic alteration, menin, Smad3 and the VDR probably contribute to dysregulated parathyroid cell proliferation and tumorigenesis.
Menin and Bone
Both TGF−b and BMPs, which are primarily synthesized by osteo− blasts, play an important role in bone formation and remodeling [45] . In vivo, local administration of TGF−b alters expression of many genes regulating osteoblast activity, induces synthesis of matrix proteins and increases bone formation. BMP2 (amongst several others) is essential for osteoblastic growth and differen− tiation as well as bone formation.
Homozygous menin inactivation in mice is embryonic lethal and some fetuses exhibit clear defects in cranial and facial develop− ment [5] . Heterozygous menin knockout mice are of normal phe− notype (as are humans harboring a germline inactivating muta− tion in one MEN1 gene allele) indicating haplosufficiency with re− spect to this particular function of menin [5, 7] . Since cranial bones are formed by intramembranous ossification, these find− ings suggested that menin might play an important role in bone formation (Fig. 2) . We have demonstrated that menin is required for the commitment of multipotential mesenchymal stem cells to the osteoblast lineage [46] . This occurred, in part, by the roles played by menin in facilitating BMP signaling via Smads and the transcriptional activity of the key osteoblast regulator, Runx2 [46, 47] . Menin interacted physically and functionally with Smad1, Smad5 and Runx2 in mesenchymal stem cells [47] . In com− mitted osteoblasts, these interactions were, for the most part, lost and menin inhibited later osteoblastic differentiation. This oc− curred, in part, through menin interacting with the TGF b /Smad3 pathway [47] . In committed osteoblasts, AP−1 factor JunD pro− motes differentiation and interacts with menin, both physically and functionally [48] . Menin also suppresses osteoblast matura− tion, partly by inhibiting the differentiation actions of JunD [48] .
Perspective
One report has provided preliminary evidence that embryonic fi− broblasts from Men1 −/− mice are less responsive to TGF−b [49] . Fur− ther work with these cells as well as tissue−specific Men1 knock− out mice are likely to provide additional insights into the roles played by menin in TGF−b superfamily member signaling. 
